Recommendations for Eating Disorder Screening Prior to GLP-1 Treatment

Recent guidance calls for thorough screening for eating disorders before prescribing glucagon-like peptide-1 receptor agonists (GLP-1RAs) due to the associated risks of appetite suppression in vulnerable individuals. The consensus suggests careful monitoring and tailored approaches for patients on these medications.

Want to explore the research behind this topic?Search the NPRL

Background on GLP-1 Receptor Agonists

Initially developed to manage type 2 diabetes, GLP-1RAs are now also used in weight-loss strategies. These medications not only suppress appetite but may also lower blood glucose and blood pressure, slow gastric emptying, and facilitate weight reduction. However, the application of these drugs among individuals susceptible to disordered eating raises important safety considerations.

While some early investigations indicated a decrease in binge eating and related psychopathology, particularly in binge eating disorder cases, the overall evidence remains inconclusive. Most notably, a rigorously controlled trial found no significant reduction in binge frequency compared to placebo, despite achieving greater weight loss. There is a notable concern regarding the potential for relapse or the emergence of new eating disorders during treatment.

Consensus Study on Screening Recommendations

To address the need for a structured approach, a recent study published in World Psychiatry utilized a modified Delphi method to establish expert consensus on the use of GLP-1RAs among individuals with eating disorders. This involved an initial core team of 12 experts, which expanded to a 45-member panel that included clinicians, researchers, and individuals with personal experiences of eating disorders or GLP-1RA treatments.

The panel reached a consensus of at least 70% on several recommendations, achieving an average agreement of 91.7% across various topics.

Notably, 94.7% endorsed the need for clinicians to screen every patient for current or historical eating disorders prior to initiating GLP-1RA treatment.

A succinct screening tool consisting of three to five questions was supported by 89.5% of panel members.

Implications of Recommendations

It was unanimously agreed (100%) that individuals with active eating disorders, particularly anorexia nervosa and bulimia nervosa, should generally avoid GLP-1RAs. This recommendation highlights the necessity for vigilance, especially among those with a prior history of such disorders. Importantly, the panel called for individualized monitoring of physical and psychological signs throughout the treatment process, with 84.2% consensus on this need.

The monitoring should extend beyond simply tracking weight loss to incorporate aspects such as eating-disorder psychopathology, nutrition, psychological health, and overall quality of life.

Should any symptoms develop during treatment, 92.1% of experts support options such as psychoeducation, specialist referral, and, depending on symptom severity, possibly discontinuation of the medication.

CNP Takeaway

THE CNP TAKEAWAY

Screening for eating disorders before commencing GLP-1RAs is crucial to mitigate risks associated with these medications for vulnerable individuals. Ongoing monitoring and tailored care strategies are essential components of safe treatment.